Identifying CDCA3 as a pivotal biomarker for predicting outcomes and immunotherapy efficacy in pan-renal cell carcinoma

Hongwei Luo,Huichan He,Zezhen Liu,Yuting Liu,Feifei Hou,Yao Xie,Le Zhang,Jianming Lu,Shan Tang,Weide Zhong
DOI: https://doi.org/10.21037/tau-24-233
2024-10-01
Translational Andrology and Urology
Abstract:Keywords: Cell division cycle-associated 3 ( CDCA3 ); renal cell carcinoma (RCC); prognosis; immunotherapy; biomarker
urology & nephrology,andrology
What problem does this paper attempt to address?